PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A 3% lemongrass essential oil inhaler was evaluated for its efficacy in reducing nicotine dependence via modulation of nAChRs [PMID:42283179]
Acute administration of lemongrass results in a decrease in blood pressure in both healthy and hypertensive animals [PMID:36290288]
Aqueous extract presented an antitumor effect and improved the chemotherapy activity of docetaxel in DU-145 cells [PMID:33438563]
Lemongrass demonstrated antioxidant and anticancer activity against SiHa cell lines [PMID:34282694]
Hydroethanolic and aqueous extracts corrected ovarian damage, decreased serum testosterone, and reduced cystic follicles [PMID:41532033]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 37641691 (2023) — Formulation of lemongrass oil (Cymbopogon citratus)-loaded solid lipid nanoparticles: an in vitro assessment study. · 3 Biotech
- 2.PMID: 41532033 (2026) — Lemongrass (Cymbopogon citratus) Extracts Ameliorate Polycystic Ovary Syndrome in Rats by Inhibiting Follicular Atresia and Modulating Ghrelin and Leptin. · Biochemistry research international
- 3.PMID: 38357460 (2024) — A comprehensive lemongrass (Cymbopogon citratus) leaf dataset for agricultural research and disease prevention. · Data in brief
- 4.PMID: 32251453 (2020) — Lemongrass (Cymbopogon citratus) oil: A promising miticidal and ovicidal agent against Sarcoptes scabiei. · PLoS neglected tropical diseases
- 5.PMID: 36270554 (2022)